![Elias Papatheodorou](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Elias Papatheodorou
Vorstandsvorsitzender bei
Calliditas Therapeutics Suisse SA
Profil
Elias Papatheodorou is currently Chief Executive Officer & Director at Calliditas Therapeutics Suisse SA since 2015.
Since 2022, holds the position of Chief Executive Officer & Managing Director at HepaRegeniX GmbH, with the managing director title starting in 2024.
Also serves as Director at Tribune Therapeutics AB. Former roles include Chief Executive Officer at Novosom Verwaltungs GmbH from 2004 to 2009, Chief Executive Officer at Genticel SA, Chief Executive Officer & Director at Calliditas Therapeutics France SAS from 2017 to 2021, Chairman at Priaxon AG, Independent Chairman at Memo Therapeutics AG, Senior VP-Business Development & Operations at MediGene AG, Principal at Philip Morris USA, Inc., and Chief Business Officer at Covagen AG.
Education includes undergraduate studies at Ithaca College and graduate studies at Cornell University.
Aktive Positionen von Elias Papatheodorou
| Unternehmen | Position | Beginn |
|---|---|---|
Calliditas Therapeutics Suisse SA
 Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Develops small molecule therapeutics that selectively inhibit NOX enzymes | Vorstandsvorsitzender | - |
HepaRegeniX GmbH
 HepaRegeniX GmbH BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops novel therapies for the treatment of acute and chronic liver diseases | Vorstandsvorsitzender | 22.10.2024 |
Tribune Therapeutics AB
 Tribune Therapeutics AB Miscellaneous Commercial ServicesCommercial Services Operates as preclinical biopharmaceutical company that develops medicines to treat patients with fibrotic diseases | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Elias Papatheodorou
| Unternehmen | Position | Ende |
|---|---|---|
Memo Therapeutics AG
 Memo Therapeutics AG BiotechnologyHealth Technology Develops a disruptive platform technology for antibody discovery | Vorsitzender | 08.07.2024 |
| GENKYOTEX SA. | Vorstandsvorsitzender | 01.12.2021 |
Genticel SA
 Genticel SA BiotechnologyHealth Technology Develops vaccines for patients infected with human papillomavirus | Vorstandsvorsitzender | - |
Priaxon AG
 Priaxon AG Miscellaneous Commercial ServicesCommercial Services Operates as a drug discovery company for small molecule therapeutics | Vorsitzender | - |
Covagen AG
 Covagen AG BiotechnologyHealth Technology Develops next generation protein drugs for the treatment of inflammatory diseases and cancer | Corporate Officer/Principal | - |
Ausbildung von Elias Papatheodorou
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
12
Beziehungen ersten Grades
13
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 13 |
|---|---|
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Develops small molecule therapeutics that selectively inhibit NOX enzymes | Health Technology |
MediGene AG
 MediGene AG BiotechnologyHealth Technology Engages in the clinical research and development of novel drugs against cancer & autoimmune diseases with focus on personalized immunotherapies | Health Technology |
Ithaca College
 Ithaca College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Philip Morris USA, Inc.
 Philip Morris USA, Inc. TobaccoConsumer Non-Durables Manufactures and distributes cigarettes and related tobacco products | Consumer Non-Durables |
Priaxon AG
Priaxon AG Miscellaneous Commercial ServicesCommercial Services Operates as a drug discovery company for small molecule therapeutics | Commercial Services |
Novosom Verwaltungs GmbH
 Novosom Verwaltungs GmbH BiotechnologyHealth Technology Develops liposomal technology for the delivery of DNA based therapeutics | Health Technology |
Genticel SA
Genticel SA BiotechnologyHealth Technology Develops vaccines for patients infected with human papillomavirus | Health Technology |
Covagen AG
Covagen AG BiotechnologyHealth Technology Develops next generation protein drugs for the treatment of inflammatory diseases and cancer | Health Technology |
Memo Therapeutics AG
Memo Therapeutics AG BiotechnologyHealth Technology Develops a disruptive platform technology for antibody discovery | Health Technology |
HepaRegeniX GmbH
HepaRegeniX GmbH BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops novel therapies for the treatment of acute and chronic liver diseases | Health Technology |
Calliditas Therapeutics France SAS
 Calliditas Therapeutics France SAS Miscellaneous Commercial ServicesCommercial Services Engages in biotechnology research and development | Commercial Services |
Tribune Therapeutics AB
Tribune Therapeutics AB Miscellaneous Commercial ServicesCommercial Services Operates as preclinical biopharmaceutical company that develops medicines to treat patients with fibrotic diseases | Commercial Services |
